Previous 10 | Next 10 |
2024-05-07 16:32:16 ET More on Rigel Pharmaceuticals Rigel Pharmaceuticals: No Respect With Little Justification, Worth Considering A Buy Rigel Pharmaceuticals, Inc. (RIGL) Q4 2023 Earnings Call Transcript Rigel Pharmaceuticals: Gavreto Deal Expands Growth Prospects ...
Rigel Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire First quarter 2024 total revenue of $29.5 million , which includes TAVALISSE ® net product sales of $21.1 million and REZLIDHIA ® net product sales of ...
Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...
Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update PR Newswire SOUTH SAN FRANCISCO, Calif. , April 30, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will re...
2024-04-29 07:00:00 ET Summary Rigel Pharmaceuticals has multiple approved agents and a modest pipeline of developmental projects. The company has a stable financial position with growing sales and a new product in its stable. Rigel Pharmaceuticals faces both strengths and ris...
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymp...
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer PR Newswire SOUTH SAN FRANCISCO, Calif. , March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, ...
2024-03-05 22:20:25 ET Rigel Pharmaceuticals, Inc. (RIGL) Q4 2023 Earnings Conference Call March 5, 2024 4:30 AM ET Company Participants Ray Furey - Executive Vice President, General Counsel and Corporate Secretary Raul Rodriguez - President and Chief Executive Offic...
2024-03-05 16:08:23 ET More on Rigel Pharmaceuticals Rigel Pharmaceuticals: Gavreto Deal Expands Growth Prospects Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report Rigel Pharmaceuticals acquires U.S. rights to Gavreto ...
Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update PR Newswire Fourth quarter 2023 Total Revenue of $35.8 million which includes TAVALISSE ® net product sales of $25.7 million and REZLIDHIA ® net produ...
News, Short Squeeze, Breakout and More Instantly...
Rigel Pharmaceuticals Inc. Company Name:
RIGL Stock Symbol:
NASDAQ Market:
Rigel Pharmaceuticals Inc. Website:
2024-06-27 09:02:05 ET Rigel Pharmaceuticals (RIGL) announced stock split at a ratio of 1-for-10 on 2024-06-27 ... Full story available on KlickAnalytics.com
Rigel Announces Reverse Stock Split PR Newswire SOUTH SAN FRANCISCO, Calif. , June 25, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will effect a reverse stock split of its issued and outstanding shares of common st...
Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application PR Newswire GAVRETO will be available from Rigel in the U.S. beginning June 27, 2024 SOUTH SAN FRANCISCO, Calif. , June 24, 2024 /PRNewswire/ -- Rigel Pharmac...